Navigation Links
VIVUS to Present at Lazard Capital Markets Healthcare Conference
Date:11/11/2009

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Lazard Capital Markets 6th Annual Healthcare Conference.

The VIVUS presentation will take place at The St. Regis in New York, NY on Wednesday, November 18, 2009 at 1:45 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                 Investor Relations: The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
    650-934-5200
                                Media Relations:    Pure Communications, Inc.
                                                    Dan Budwick
                                                    973-271-6085

'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Amgen (NASDAQ: AMGN ... Authorization Application (MAA) to the European Medicines Agency ... AMG 416) for the treatment of secondary hyperparathyroidism ... (CKD) on hemodialysis therapy. If approved, etelcalcetide will ... administered intravenously. Etelcalcetide is a novel ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ... the "An Introduction to Medical Device Software: ... 2015)" conference to their offering. ... to the regulations and requirements that apply to ... interactive, using real life examples and state-of- the-art ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has announced ... (London, UK - November 16-17, 2015)" conference to ... modules concerning Pharmacovigilance are a major departure in terms ... Europe . The intention of the course is ... how they overlap and fit together and what Companies ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... , BATESVILLE, Ind. , Feb. 3 ... versus prior year , Reported diluted earnings per ... and reported earnings per share of $0.23 in the prior year ... prior year , Company updates annual guidance for ...
... , PITTSBURGH , Feb. 3 ... patients and doctors work together to fight cancer.  Now, drug ... results which can help to determine individual cancer treatment plans ... produced by Precision Therapeutics, Inc., a life sciences company in ...
Cached Medicine Technology:Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 2Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 3Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 4Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 5Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 6Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 7Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 8Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 9Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 10Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 11Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 12Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 13Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 14Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 15Hill-Rom Reports Double Digit Earnings Per Share Growth for First Quarter 16Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions 2Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions 3
(Date:9/3/2015)... ... September 03, 2015 , ... When looking at the types of people who have ... of two categories: those that have a weak appetite or those that have a fast ... to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. , The ...
(Date:9/3/2015)... ... September 03, 2015 , ... Leading post-acute electronic medical ... will be joining the company’s executive leadership team as VP of Product and ... experience in healthcare product and project management. He has been with HealthWyse since ...
(Date:9/2/2015)... Colorado (PRWEB) , ... September 03, 2015 , ... ... its wellness services - two retreats geared towards kick-starting and inspiring wellness in the ... love being a part of developing a whole mind-body approach to fitness - we ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors ... public servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had ... led the magazine to tap the National League for Nursing’s outspoken CEO, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading producer ... leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ... in Boston. , Larry Renfro, CEO of Optum, will deliver the morning address. ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3
... the Nation in Giving as Demand for Nonprofit Services Peaks ... More than half of Coloradans report that they will ... during the economic downturn, according to " Generous Colorado: Why ... which reflects data from surveys conducted October 2008. With demand ...
... Bermuda, Dec. 4 The Board of Directors of Tyco International Ltd. ... cash dividend of $0.20 per common share. The dividend is payable ... 2009. , , ABOUT TYCO ... is a diversified, global company that provides vital products and services to ...
... In the wake of the findings of its ... its importance in elite physical performance, Nestle has,launched a ... athletes,engaged in different kinds of sports. The program will ... sports nutrition in the future, which,should lead to a ...
... calling for more studies into the practice of forcing ... showed that there have been very few rigorous investigations ... the latest Journal of Advanced Nursing , suggests ... to be in their thirties with a diagnosis of ...
... Stem cells derived from bone marrow may serve as ... epidermolysis bullosa (EB), a disorder characterized by extraordinarily fragile ... Blood , the official journal of the American Society ... characterized by extraordinarily fragile skin and blistering on touch, ...
... Method to Redirect the Specificity of Immune Cells and ... GAITHERSBURG, Md., Dec. 4 MaxCyte, ... scale, non-viral cell loading systems, announces that Joseph C. ... at MaxCyte, will give a presentation on a breakthrough ...
Cached Medicine News:Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4Health News:Nestle Launches New Research Program on the Specific Nutritional Needs of Athletes 2Health News:Nestle Launches New Research Program on the Specific Nutritional Needs of Athletes 3Health News:Coerced medication used in psychiatric care despite lack of clinical evidence 2Health News:Coerced medication used in psychiatric care despite lack of clinical evidence 3Health News:Bone marrow-derived stem cells may offer novel therapeutic option for skin disorder 2Health News:Bone marrow-derived stem cells may offer novel therapeutic option for skin disorder 3Health News:MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology 2
Look to the intuitive iLab System to deliver the best IVUS image quickly and easily. This easy-to-use installed system with tableside controller is the Clear Choice for IVUS....
... full picture ,CardioPAL SAVI is the ... cial Intelligence, with a smart algorithm running ... on each device. The Diogenes algorithm continuously ... rate, rhythm, morphology, and p-wave abnormalities ...
A patient care system tailored to your specific needs that supports current and previous-generation ICDs and pacemakers....
The Rio Catheter is designed to simplify your intravascular interventions by removing thrombus and restoring epicardial flow to the procedure....
Medicine Products: